Hong Kong, August 21, 2025 — Xellera Therapeutics, a forefront CDMO in Cell and Gene Therapy (CGT) and Advanced Therapy Products (ATP), announces a strategic focus on developing innovative diagnostic and treatment approaches for infections caused by Mycoplasma pneumoniae, a leading cause of respiratory illness worldwide.
Mycoplasma pneumoniae is a significant bacterial pathogen responsible for causing atypical pneumonia and other respiratory tract infections, particularly affecting children and young adults. The microorganism's resistance to common antibiotics presents ongoing challenges for effective treatment.

Xellera Therapeutics is committed to enhancing healthcare outcomes by leveraging its advanced manufacturing and development capabilities to support new therapies targeting Mycoplasma pneumoniae. By integrating cutting-edge technology and rigorous quality standards, the company aims to accelerate the development, testing, and commercialization of next-generation treatments that can effectively combat this pathogen.
“Addressing Mycoplasma pneumoniae infections requires innovative solutions, and we are proud to contribute our expertise to this critical area of respiratory health, Chief Scientific Officer at Xellera Therapeutics. “Our advanced capabilities will enable faster development of safe, effective therapies that can make a real difference for patients worldwide.”
For further details on Xellera Therapeutics’ initiatives regarding Mycoplasma pneumoniae and other advanced therapy developments, please visit https://www.xelleratherapeutics.com/services/bioanalytical-testing/.

About Xellera Therapeutics:
Xellera Therapeutics is a leading CDMO specializing in GMP-compliant manufacturing and development services for Cell and Gene Therapy (CGT) and Advanced Therapy Products (ATP). The company partners with innovators globally to accelerate breakthrough therapies.

Name: Xellera Therapeutics
Title: Xellera Therapeutics enhances quality assurance with advanced release testing services
Email: [email protected]
Phone: +852 2618 3356
Website: https://www.xelleratherapeutics.com/